Agenus Inc
A biotech company that develops cancer treatments by rallying the body's own immune system, it makes antibody therapies that help immune cells recognize and attack tumors. Founded in 1994 as Antigenics by Dr. Garo Armen and Dr. Pramod Srivastava, it built early heat-shock cancer vaccines before renaming itself Agenus in 2011 to signal a broader mission. Its saponin-based QS-21 Stimulon adjuvant is the immune-boosting ingredient in vaccines like GSK's Shingrix shingles shot.
Granted 1.24M · Bought 500.0K · Sold 82.1K
Bought 25.0K
Granted 39.3K
Granted 354.6K · Sold 38.7K
Granted 39.0K
Granted 93.2K · Sold 11.1K
Granted 6.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Armen Garo HSee Remarks, Director · 80 transactions | — | 426.5K | 1.24M | 500.0K | 82.1K |
| Wiinberg UlfDirector · 1 transaction | +25.2% | 124.1Kas of Nov 2023 | — | 25.0K | — |
| Hirsch Susan BDirector · 8 transactions | +770.6% | 118.7Kas of Nov 2023 | 39.3K | — | — |
| O'Day Steven JChief Medical Officer · 5 transactions | — | 57.1Kas of Jun 2025 | 354.6K | — | 38.7K |
| Wright TimothyDirector · 1 transaction | +9.9% | 55.4Kas of Nov 2023 | — | — | — |
| Harrison Thomas LDirector · 5 transactions | — | 39.0K | 39.0K | — | — |
| Klaskin Christine MPFO & PAO · 5 transactions | -73.5% | 23.5Kas of Jun 2025 | 93.2K | — | 11.1K |
| Buell JenniferDirector · 10 transactions | -84.5% | 19.7Kas of May 2025 | 6.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +393.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.